Podcasts about antibiotic resistance

Deprescribing thyroid and other meds in older adultsCan I safely take serrapeptase for longer than four weeks?I want to take nattokinase but isn't there a 'clot dislodging' risk?Could you discuss C. difficile and how to treat it?

Henry Miller describes a "tour de force" at MIT where AI is used to discover new molecules to fight antibiotic resistance. This technology identifies structures that kill pathogens like staphylococcus and gonorrhea. (14/16)1750

Now do we have to start worrying about Hantavirus? Digestive enzymes for pancreatic insufficiency; Space exploration yields new treatments for resistant bacterial infections; Alternatives to prednisone for autoimmune hearing loss; Casey Means bows out of Surgeon General nomination—next up, Nicole Saphier; Multivitamins found to slow biological aging.

In this podcast episode... Penicillin has been around for almost 100 years, but its effectiveness against certain medical conditions is starting to fail. We catch up with a scientist whose team at UConn is looking for something better than pencillin in the war against resistant bacteria.

Arreaza: Welcome back tothe Rio Bravo qWeek Podcast! My name is Dr. Hector Arreaza, I am a family physician and faculty member in the Rio Bravo Family Medicine Residency Program. Today I am joined by two excellent medical students who will introduce themselves now, welcome, guys! Mehr: Thank you for the introduction! My name is Mehr Boparai, third year medical student at WesternU COMP-NW. Jeremy: And my name is Jeremy Pan, also a third-year medical student at WesternU COMP Pomona and we will be discussing a very prevalent topic today in the clinical world that is arguably becoming one of the biggest threats to modern medicine: antibiotic resistance. Mehr: That's right! Imagine this scenario: a routine infection, something we've treated easily for decades, suddenly becomes life-threatening because the drugs we always thought we could rely on just don't work anymore. You likely ran into this problem just last week with one of your patients! That's not science fiction. That's happening every day in hospitals across the world. Dr. Arreaza: I agree, antibiotic resistance must be taken seriously. I increased my awareness in 2023, when I attended a medical research conference in Carmel(which is a popular conference that takes place in that beautiful town). I heard Dr. David Gilbert, a famous and accomplished ID doctor who helped develop the Sanford Guide to Antimicrobial Therapy, he warned everyone about antibiotic resistance as one of the biggest threats for humanity, the other two were a nuclear bomb and an epidemic. Jeremy: Woah, comparing antibiotic resistance to a nuclear bomb is absolutely crazy, but likely very real!! Well today, we're going to be focusing on five of the most common infections or “bugs” you'll see in a hospital setting. We'll talk about what typically causes them, what antibiotics we used to rely on, and what happens when resistance decides to enter the picture. Mehr: If you are a medical student (or resident), you understand that dreaded feeling when an attending asks “what antibiotics should we start?” But don't worry, in this episode, we hope to address the decision-making process in a simple framework. What is Antibiotic Resistance? Dr. Arreaza:  Before we jump into specific common infections and pathogens, let's cover our basics. Antibiotic resistance occurs when bacteria evolve to survive drugs designed to kill them. This can happen through genetic mutations or by getting resistance genes from other bacteria. Why does this matter? Jeremy: It matters because antibiotics play a huge role in modern medicine. Without them, surgeries, chemotherapy, organ transplants—even childbirth—become significantly more dangerous. Mehr: According to the CDC, in the U.S. alone, antibiotic-resistant infections affect over 2.8 million people each year and cause more than 35,000 deaths! So, when we talk about resistance, we're not just talking about inconvenience for treatments. We're talking about a fundamental threat to healthcare. Staph aureus Dr. Arreaza: So, if you have a patient who comes in with a skin infection or is maybe showing signs of pneumonia or bacteremia, what is one of the most common bugs that you should think about? Jeremy: Staph aureus! Typically to treat methicillin-sensitive strains (MSSA), we would utilize antibiotics like nafcillin, oxacillin, or cefazolin. But there is one strain in particular that is worrisome, Mehr? Mehr: yeap, that would have to be MRSA, one of the most well-known resistant organisms. MRSA is resistant to all beta-lactam antibiotics, which means we can say goodbye to all penicillin and most cephalosporins. Dr. Arreaza: And what is the first antibiotic that comes to mind if we see MRSA on a culture in the hospital? Mehr: Vancomycin! Alternative treatments include linezolid and daptomycin depending on the type of infection. But what is the problem that we are starting to see? Jeremy: You guessed it, cases of resistance to vancomycin are starting to appear—VRSA. These cases are still uncommon today, but these findings show a worrying trend, that we will eventually start running out of reliable options. Dr. Arreaza: Fortunately, VRSA infections are extremely rare, with only 14-16 documented cases in the United States. As of 2019, 52 VRSA strains have been identified in the United States, India, Iran, Pakistan, Brazil, and Portugal. Let's keep an eye on VRSA in the future.  E. coli Dr. Arreaza: Alright, so let's say you have a patient with dysuria, urinary frequency, maybe even a catheter in place. What's the most common bug you're thinking of? Mehr: That one's a classic, we are thinking E. coli. Jeremy: Exactly. E. coli is the leading cause of urinary tract infections, especially in both community and hospital settings. Dr. Arreaza: So Jeremy, what are we using for uncomplicated UTIs? Jeremy: We usually think of trimethoprim-sulfamethoxazole, nitrofurantoin, or sometimes fosfomycin. And in more complicated cases, we might consider fluoroquinolones like ciprofloxacin. Mehr: But here's where things get tricky. Resistance to TMP-SMX and fluoroquinolones has been increasing significantly. In some areas, resistance rates are over 20–30%, which really changes your empiric choices. Conclusion: Dr. Arreaza: So we've talked about five major organisms today: Staph aureus, E. coli, Klebsiella, Pseudomonas, and C. diff. What's the overarching takeaway of the discussion? Jeremy: The main takeway is that antibiotic resistance is already here, and it's affecting some of the most common infections we see in clinical practice on a day-to-day basis. Mehr: And as students and future physicians, it's important to not just memorize antibiotics, but understand why we're choosing them. Dr. Arreaza: Exactly. Always think: What organism am I targeting? What are the local resistance patterns? And can I narrow therapy once I have cultures? Jeremy: And maybe most importantly—don't overuse antibiotics, especially in cases when they're not needed. Mehr: Because the more we use them, the faster we lose them. Dr. Arreaza: I'd like to share the story I listed to in a RadioLab episode about Dr Steffanie A. Strathdee, one of the most influential ID doctors in the world and Co-Director at the Center for Innovative Phage Applications and Therapeutics (IPATH). She shared that her husband got infected by Acinetobacter baumannii, an opportunistic infection that can cause severe infection. After trying many antibiotics, he was treated with “phages”, “bacteriophages”. So, that's part of “thinking out of the box”. Jeremy: Thank you all for tuning in to the Rio Bravo qWeek podcast series and thank you Dr. Arreaza for having Mehr and me on the podcast today! Stay informed, stay curious—and we'll see you next time Mehr: Guys! I had so much fun! We hope this episode helped simplify antibiotic selection for the most common infections and bugs seen in a hospital setting and gave you a framework you can for initial treatments and cases of antibiotic resistance. Thanks for hanging out with us!  Dr. Arreaza: And remember, antibiotics are one of the most powerful tools we have in medicine. Let's use them wisely. This is Dr. Arreaza, signing off.  _____________________ References: Radiolab. (2026, March 27). Antibiotic apocalypse. WNYC Studios. https://radiolab.org/podcast/antibiotic-apocalypse Metlay, J. P., Waterer, G. W., Long, A. C., et al. (2019). Diagnosis and treatment of adults with community-acquired pneumonia: An official clinical practice guideline of the American Thoracic Society and Infectious Diseases Society of America. American Journal of Respiratory and Critical Care Medicine, 200(7), e45–e67. https://www.idsociety.org/practice-guideline/community-acquired-pneumonia-cap-in-adults/ Gilbert, D. N., Chambers, H. F., Saag, M. S., et al. (2026). The Sanford Guide to Antimicrobial Therapy (56th ed.). Antimicrobial Therapy, Inc. Centers for Disease Control and Prevention. (2025, September 17). Antibiotic stewardship resource bundles. https://www.cdc.gov/antibiotic-use/hcp/educational-resources/stewardship/index.html Theme song, Works All The Time by Dominik Schwarzer, YouTube ID: CUBDNERZU8HXUHBS, purchased from https://www.premiumbeat.com/.   Even without trying, every night you go to bed a little wiser. Thanks for listening to Rio Bravo qWeek Podcast. We want to hear from you, send us an email at RioBravoqWeek@clinicasierravista.org, or visit our website riobravofmrp.org/qweek. See you next week!

This week scientists confirm the link between changes to the microbiome and later development of Parkinson's Disease, a super speedy microfluidic way to diagnose infection and probe antibiotic susceptibility, how many infections does daycare cause in your toddler, and the breakthrough capable of boosting laser power by orders of magnitude... Like this podcast? Please help us by supporting the Naked Scientists

From zoonotic disease to bird flu, Bohanec links animal agriculture to pandemics—and introduces ahimsa as a spiritual guide for compassionate living. #Pandemics #FactoryFarming #Ahimsa #HealthTalks

The FDA finds 1 in 10 imports of shrimp have unsafe levels of drug residues yet only tests about 1 in 1,000 shipments.

In this episode, featuring audio from a local live workshop, experts Richard Colgan, MD, and Christopher Smith, MD, explore the burden of complicated urinary tract infection (cUTI) on patients and the healthcare system, highlight advances in the treatment of complicated UTIs, and examine approaches to empiric and definitive antibiotic therapy. Topics covered include: The Burden of cUTI and Antimicrobial Resistance Changes in IDSA Guidelines for cUTI Diagnosing cUTI Selection of Empiric and Definitive Therapy Novel Treatments for cUTI Get access to all of our new podcasts by subscribing to the Decera Clinical Education Infectious Disease Podcast on Apple Podcasts, YouTube Music, or Spotify. Presenters:  Richard Colgan, MD Professor Emeritus Department of Family and Community Medicine University of Maryland School of Medicine Baltimore, Maryland Christopher Smith, MD Infectious Disease Physician Chase Brexton Healthcare Clinical Assistant Professor Shock Trauma Center, University of Maryland Medical Center Baltimore, Maryland Link to program page: https://bit.ly/3Q4TgDK Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Antibiotic-resistant superbugs could become a greater threat than cancer. Bruno and Pedro at the startup Immunethep explain how they're tackling the crisis with vaccines.We discuss how Immunethep could challenge Pfizer's $7bn+ Prevnar, and how one pharma company got on board after a representative said he doesn't believe in vaccines!---For transparency, this episode has been sponsored by Immunethep. Learn more at https://bit.ly/flot-immunethep---⭐️ ABOUT THE SPEAKERSBruno is Immunethep's co-founder and CEO, and co-founder of the startup creator Venture Catalysts. He also co-founded the tech startup Abyssal, which was acquired by marine robotics company Ocean Infinity in 2021.Co-founder and CSO Pedro is a biomedical scientist previously serving as an Assistant Researcher at i3S. He has a PhD in Biomedical Sciences from the University of Porto and boasts over 30 peer-reviewed publications.

Fifty to sixty percent of women will get a urinary tract infection at least once in their lifetime — and for many, it won't stop there. So why does almost every conversation about UTIs still end with the same answer: another antibiotic? In this episode of the Your Health University Podcast, host Jamie Preston sits down with Madison Browning, Executive Director of Clinical Services in the Specialty Department at Your Health, to explore what's actually possible when we stop reacting and start preventing. Madison oversees the urology and nephrology divisions and brings the kind of front-line clinical perspective that turns confusing medical information into something anyone can act on. Together, they cover: Why repeated antibiotic use can actually make you more prone to future infections — and what antibiotic resistance really means for your body The honest truth about cranberry: there is science behind it, but probably not in the form you've been using What D-Mannose is, how it works, and why it practically fills the hooks bacteria use to grab onto your urinary tract Vaginal estrogen — the most evidence-backed, most underused prevention option for postmenopausal women, and why the word "estrogen" shouldn't automatically trigger fear The lifestyle changes that cost nothing, require no prescription, and form the foundation of any prevention plan This isn't about abandoning medical care. It's about having a better conversation with your provider — one that goes beyond treating the infection in the moment and starts asking why it keeps happening at all. www.YourHealth.Org

Doctor and special correspondent Avir Mitra takes Executive Editor Soren Wheeler, plus a live studio audience, on a journey from the operating room to inside the body to the farm to the sewers and back again—searching for answers to an alarming threat to humanity's existence as we know it: antibiotic resistance in bacteria.  This live show, performed in New York City and also in Little Rock, Arkansas, is part of a series we're doing with Avir that we are calling “Viscera.” Each event is a conversation that takes the audience on a journey into a quirk or question or mystery inside of us, and gives them a visceral experience of the viscera within us. The previous installment of the series was called “The Elixir of Life.” (https://radiolab.org/podcast/the-elixir-of-life)Special thanks to all of Little Rock Public Radio (especially Grace Zafasi and Jonathan Seaborn), Thomas Patterson, The Greene Space staff, CALS Ron Robinson Theater, Tom Philpott, Stephen Roach, Kate Shaw, Alex Wong, Maryn McKenna, and Kerri McClimen.If you are a patients or a doctor, and you are interested in phage therapy, please contact IPATH@ucsd.edu EPISODE CREDITS:  Reported by - Avir Mitra Produced by - Jessica Yung Sound design contributed by - Jeremy Bloom and Jessica Yung Fact-checking by -Natalie Middleton EPISODE CITATIONS: Videos - Check out the video from the Viscera live show (and a bonus Q&A with Bruce Stewart-Brown and Steffanie Strathdee) on Radiolab's YouTube (https://zpr.io/3BK9MqJYVKQA). A deep dive (https://zpr.io/WNQNfgiNvKeZ) on bacteriophages with Avir Mitra and Steffanie Strathdee, also on Radiolab's Youtube.. Books - The Perfect Predator (https://theperfectpredator.com/) by Dr. Steffanie Strathdee's telling of her battle against a killer superbug. Plucked (https://zpr.io/PudGMEuzgU9X) by Maryn Mckenna a detailed accounting of chicken farming's practice of using antibiotics. Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)! Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today. Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

In this Season 4 premiere of Speaking of Mol Bio, host Steve Lewis speaks with Dr. Nina Pollak from the University of the Sunshine Coast about the development of a single-dose vaccine aimed at protecting endangered koalas from Chlamydia pecorum. The disease is a major threat to koala populations across eastern Australia, contributing to infertility, blindness, and increased mortality. Pollak's work focuses on optimizing the production and quality control of vaccine antigens while supporting regulatory approval and field trials that ultimately led to a conditional minor-use permit from Australia's veterinary regulatory authority.  The vaccine relies on recombinant versions of the major outer membrane protein (MOMP) from three dominant chlamydial genotypes. Using standard molecular biology techniques, including gene cloning in E. coli, His-tag purification, SDS-PAGE verification, western blotting, and mass spectrometry, Pollak's team produces and verifies these vaccine antigens before combining them with adjuvants to stimulate protective immune responses. Beyond the science, the episode explores the challenges of conservation-focused vaccinology: field vaccination of wild animals, limited commercial incentives, and the importance of methods for monitoring disease prevalence. Pollak also reflects on the collaborative nature of the decade-long project and offers advice to young scientists pursuing difficult but meaningful research challenges. Subscribe to get future episodes as they drop and if you like what you're hearing we hope you'll share a review or recommend the series to a colleague.  Visit the Invitrogen School of Molecular Biology to access helpful molecular biology resources and educational content, and please share this resource with anyone you know working in molecular biology. For Research Use Only. Not for use in diagnostic procedures.

Medical Notes: Needle-Free Injections, The Benefits Of A Forgotten Skeletal Tissue, And The Importance Of Demographic Inclusiveness In Science The ongoing war on antibiotic resistance. Science has rediscovered a "forgotten" skeletal tissue that could be the future of facial reconstruction. A common bedtime habit might be preventing your brain from performing its nightly "deep clean." Building public trust in science may rely on appearances. Host: Maayan Voss de Bettancourt   Producer: Kristen Farrah Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

A strange brew that's hard to resist, even for a modern day microbe. In the war on devilish microbes, our weapons are starting to fail us. The antibiotics we once wielded like miraculous flaming swords seem more like lukewarm butter knives. But in this episode, originally released in 2015, we follow an odd couple, of a sort, to a storied land of elves and dragons. There, they uncover a 1,000-year-old secret that makes us reconsider our most basic assumptions about human progress and wonder: what if the only way forward is backward? Special thanks to Steve Diggle, Professor Roberta Frank, Alexandra Reider and Justin Park (our Old English readers), Gene Murrow from Gotham Early Music Scene, Marcia Young for her performance on the medieval harp and Collin Monro of Tadcaster and the rest of the Barony of Iron Bog. Can't get enough of that sweet, sweet antibiotic resistance content? Then you'll be over the moon about next week's release. It's the podcast cut of our most recent installment of our live show series called Viscera. This one features executive editor Soren Wheeler and Avir Mitra, and it's all about how our millenia's-long war against bacteria came to a tipping point in this modern age. Subscribe or follow our show on your favorite streaming platform and you'll be the first to know when it drops. EPISODE CREDITS:  Reported by - Latif Nasser Produced by - Matt Kielty and Soren Wheeler EPISODE CITATIONS: Articles - Uncovering the multifaceted mechanism of action of a historical antimicrobial (https://zpr.io/mucw6Td6LBxT) by Harrison, F et al, 2026 bioRxv (PREPRINT). In this article Freya and her team describe the mechanisms under which Bald's Remedy actually works. Signup for our newsletter!! It includes short essays, recommendations, and details about other ways to interact with the show. Sign up (https://radiolab.org/newsletter)! Radiolab is supported by listeners like you. Support Radiolab by becoming a member of The Lab (https://members.radiolab.org/) today. Follow our show on Instagram, Twitter and Facebook @radiolab, and share your thoughts with us by emailing radiolab@wnyc.org.Leadership support for Radiolab's science programming is provided by the Simons Foundation and the John Templeton Foundation. Foundational support for Radiolab was provided by the Alfred P. Sloan Foundation.

In this episode, we break down a major factor in treating SIBO and preventing recurrence: biofilm disruption. You'll learn how to identify the telltale signs of biofilms, the steps to our proven treatment protocol, and discover the dietary and supplement strategies that support lasting gut recovery. Our approach is backed by our recently published study, Biofilm Disruption Enhances Antimicrobial Therapy for Small Intestinal Bacterial Overgrowth and Intestinal Methanogen Overgrowth. Read the full findings here:https://pubmed.ncbi.nlm.nih.gov/41394228/.    If you've struggled with recurring SIBO and felt like nothing works, this episode will guide you to effective solutions.  

Broadcast from KSQD, Santa Cruz on 3-05-2026: Dr. Dawn demonstrates how to critically read a science paper using a widely-publicized study claiming adolescent cannabis use causes psychotic, bipolar, and anxiety disorders. She identifies multiple methodological problems: only 5.7% of Kaiser adolescents admitted cannabis use versus 11.2% in anonymous national surveys, suggesting massive underreporting; the study conflates any use with heavy use; and with 463,000 participants, trivially small differences become statistically significant but clinically meaningless. She proposes reverse causation—that prodromal schizophrenia symptoms may drive teens to self-medicate with cannabis rather than cannabis causing psychosis. The study also included "disruptive behavior disorder" diagnoses that lack rigorous criteria, and she notes diagnostic codes are sometimes chosen for insurance reimbursement rather than accuracy. While acknowledging high-dose THC before age 16 may affect brain development, she concludes the headlines claiming causation are not supported by the actual findings. Dr. Dawn discusses how aquaculture—now producing 60% of fish consumed globally—has become a breeding ground for antibiotic-resistant pathogens. More antibiotics per kilogram are used in fish farming than in any other animal agriculture, with drugs dissolving into water and sediment where bacteria develop resistance. One study found antibiotic-resistant bacteria in over 80% of shrimp species tested across multiple countries. Through horizontal gene transfer, these resistance genes spread to human pathogens—a 1991 Latin American cholera outbreak affecting nearly a million people may have acquired drug resistance from Ecuadorian shrimp farms. Dr. Dawn reports that the FDA rejected Moderna's mRNA flu vaccine application without even reviewing it, despite trials of 41,000 people showing it was 27% more effective at preventing illness and 29% more effective at preventing hospitalization than existing vaccines. She attributes this to politicized anti-mRNA bias lacking scientific basis, noting that venture capital investors like Blackstone (who invested $750 million) will now avoid vaccine development, effectively handing this critical technology to other countries. Dr. Dawn describes the "wellness industrial complex"—pharmaceuticals, tech, testing companies, and health influencers creating content that pathologizes normal behaviors. YouTube health videos have amassed 200 billion views, and 30% of British respondents now get medical advice from AI chatbots. She cites a 400% increase in British adults seeking ADHD diagnoses, noting that analysis of top TikTok ADHD videos found less than 50% accurately reflected actual symptoms. Many influencers receive undisclosed payments to mention products, and the U.S. and New Zealand are the only countries allowing direct-to-consumer drug advertising. A caller asks about navigating Medicare after their Advantage plan was terminated with no local providers accepting remaining plans. Dr. Dawn explains that Medicare Advantage companies took extra government payments meant for wellness programs but didn't build them, and are now exiting markets as costs rise. She recommends contacting Gray Bears or AARP for free Medicare navigation assistance and suggests exploring regular Medicare with a secondary plan or direct-pay practices. /li>

You ever wonder why you can't eat just one chip? Or why chicken tastes different than it did decades ago? In this episode, I break down how the food industry engineered salt, sugar and fat to hit your brain's “bliss point,” how fast food reshaped American farming, and why profit became more important than public health. From factory-raised chickens to feedlot beef to grocery store manipulation, we're unpacking how the system was built—and what you can actually do about it. Spoiler: it's not a willpower problem. It's a design problem.IntroFoodSalt, Sugar, Fat and the Bliss PointSoda: The Original Thirst TrapHow fast food rewired American farmingProfitsWhat we can actually do as consumers?Music by Loghan LongoriaFollow us on instagram: Sergio Novoa My Limited View PodResources & Research:1. Moss, Michael. Salt Sugar Fat: How the Food Giants Hooked Us. Random House, 2013. Key themes summarized at LifeClub.org. 2. Summary of processed food engineering and industry tactics at BooksThatSlay.com. 3. Overview of addictive design and ingredient roles at SoBrief.com. 4. Discussion of food companies prioritizing taste over health in processed products. 5. Reporting on antibiotic use and public health risks in livestock farming. 6. Advocacy overview of factory farming, antibiotics, and health impacts.

Explore how poultry farming pollutes ecosystems, spreads backyard neglect, and reveals the darker side of "sustainable" animal agriculture. #ChickenFarming #EcoVeganism #FactoryFarming #HealthTalks

In 1928, a chance contaminant in Scottish physician Alexander Fleming's lab experiment led to a discovery that would change the field of medicine forever: penicillin. Since then, penicillin and other antibiotics have saved millions of lives. With one problem: the growing threat of antibiotic resistance. Today on Short Wave, host Regina G. Barber talks to biophysicist Nathalie Balaban about the conundrum — and a discovery her lab has made in bacteria that could turn the tides.Check out our episodes on extreme bacteria in Yellowstone and the last universal common ancestor. Interested in more science behind our medicines? Email us your question at shortwave@npr.org.Listen to every episode of Short Wave sponsor-free and support our work at NPR by signing up for Short Wave+ at plus.npr.org/shortwave.This episode was produced by Berly McCoy, edited by our showrunner Rebecca Ramirez and fact checked by Tyler Jones. Jimmy Keeley was the audio engineer. Learn more about sponsor message choices: podcastchoices.com/adchoicesNPR Privacy Policy

The rise of antibiotic resistance is threatening millions of lives worldwide, but “unconventional” Australian research could make obsolete medications effective again. Data released by the World Health Organization (WHO) has found that some of the most common illnesses in the world are becoming more resistant to treatment every year. Dr Maud Eijkenboom says the current approach of developing new antibiotics is losing the battle against ever-evolving viruses and bacteria. After her son struggled with a resistant disease, Dr Eijkenboom set on her own path to discover a better way eradicate the rising wave of lethal pathogens. In 2021, she founded Lixa, a Perth-based biotech company receiving international support for its “game-changing” research. In this edition of Weekend One on One, she speaks with SBS's Cameron Carr about the impact of her research, and started by explaining what Lixa is all about.

The Interdisciplinary Meeting of Antimicrobial Resistance and Innovation has launched! The first version of IMARI brought together researchers, clinicians, industry leaders and policymakers to address one of the greatest challenges in modern medicine: antimicrobial resistance" Check the highlights at IMARI.org and prepare for IMARI 2017 from January 27-29, 2027! The inaugural amazing conference took place in Las Vegas. This is the forst time that ASM and IDSA collaborate together in a scientific meeting. One of the sessions involved an unprecedent collaboration between two journals AAC and JID published by each society. To celebrate this achievement we had a session of the best AMR papers of 2025 for AAC and JID. This session will be presented here as apart of our series.  Watch this episode: https://youtu.be/XRYl7863z34 Objectives: - Review the best papers and topics of AMR in 2025 form AAC and JID. - Discuss the context of each finding and contributions to the AMR community - Elaborate on the implications for AMR, novelties and how the field is advancing. Guests:  - Ayesha Khan, Ph.D.  Assistant Professor, Pathology & Laboratory Medicine and Associate Director, Division of Clinical Microbiology Biomedical & Translational Research Track. Principal Investigator, UC3P UCI Prime Pre-Health Pathways Program. - Madison Stellfox, M.D. Ph.D. Assistant Professor of Medicine, University of Pittsburgh Medical Center, Pittsburgh, PA.  Links:  Links: AAC A microbiological and structural analysis of the interplay between sulbactam/durlobactam and imipenem against penicillin-binding proteins (PBPs) of Acinetobacter spp. https://doi.org/10.1128/aac.01627-24 JID Ampicillin/Sulbactam in Combination with Ceftazidime/Avibactam Against Metallo-β-Lactamase-Producing Carbapenem-Resistant Acinetobacter baumannii: A Genomics-Informed Mechanism-based model https://doi.org/10.1093/infdis/jiaf567 AAC Advancements in the fight against globally distributed OXA-48 carbapenemase: evaluating the new generation of carbapenemase inhibitors https://doi.org/10.1128/aac.01614-24 JID Daptomycin-Loaded Nanocarriers Facilitate Synergistic Killing of Methicillin-Resistant Staphylococcus aureus via Lipid-Mediated Interactions and Targeting https://doi.org/10.1093/infdis/jiaf492 AAC Amoxicillin-non-susceptible Streptococcus pneumoniae causing invasive pneumonia: serotypes, clones, and clinical impact https://doi.org/10.1128/aac.00237-25 JID Blood Cultures Contain Populations of Genetically Diverse Candida albicans Strains that May Differ in Echinocandin Tolerance and Fitness https://doi.org/10.1093/infdis/jiaf495 AAC Antibiofilm activity of manogepix, ibrexafungerp, amphotericin B, rezafungin, and caspofungin against Candida spp. biofilms of reference and clinical strains https://doi.org/10.1128/aac.00137-25 JID Engineered Mycobacteriophage TM4::GeNL Rapidly Determines Bedaquiline, Pretomanid, Linezolid, Rifampicin, and Clofazimine Sensitivity in Mycobacterium tuberculosis Clinical Isolates https://doi.org/10.1093/infdis/jiae438 AAC Emergence of antibiotic-specific Mycobacterium tuberculosis phenotypes during prolonged treatment of mice https://doi.org/10.1128/aac.01310-24 JID The Changing Paradigm in Infectious Diseases—Host-Directed Medicine: Implications for the Next Generation of ID Physicians https://doi.org/10.1093/infdis/jiaf497 JID Triggering Toll-Like Receptor 5 Signaling During Pneumococcal Superinfection Prevents the Selection of Antibiotic Resistance https://doi.org/10.1093/infdis/jiae239 IMARI Conference This episode is brought to you by the Antimicrobial Agents and Chemotherapy journal available at https://asm.org/aac.  If you plan to publish in AAC, ASM Members get up to 50% off publishing fees. Visit https://asm.org/joinasm to sign up. Visit https://asm.org/aac to browse issues and/or submit a manuscript. Follow Cesar on twitter at https://twitter.com/SuperBugDoc for AAC updates. 

Antibiotics have long served as a foundation of modern veterinary medicine, especially in livestock animals. Yet a growing public health threat looms as bacteria evolve to evade these vital drugs. A new study from the University of Kentucky's Martin-Gatton College of Agriculture, Food and Environment reveals that antibiotic resistance in cattle-associated bacteria could have far-reaching implications for human, animal and environmental health. Dr. Greg talks with Yosra Helmy, associate professor of One Health and Infectious Diseases in the Department of Veterinary Science and One Health Center researcher, who led the study.

The Predator's Playbook: How To Identify And Prevent Child Sexual AbuseChild abuse is a sobering reality often perpetrated by trusted individuals rather than strangers. To successfully exploit a child, predators rely on a specific playbook to gain access, trust, and secrecy. Our expert this week explains how parents can help dismantle these opportunities without needing to resort to overprotective parenting styles.Guests: Dr. Bronwen Carroll, pediatric emergency medicine physician, Boston Medical Center, assistant professor of pediatrics, Boston UniversityHost: Elizabeth WestfieldProducer: Polly Hansen  Why Are Kidney Stones Skyrocketing In Young Girls?Kidney stones, historically associated with middle-aged men, are now being diagnosed at an increasing rate in young girls. Though stones can remain undetected for years, they often cause extreme pain and nausea once they move into the ureter. Our expert discusses treatment options and possible reasons we're seeing more cases in younger patients.  Guests: Dr. Greg Tasain, attending pediatric urologist, Children's Hospital of Philadelphia, professor of surgery, University of Pennsylvania Perelman School of Medicine  Host: Greg JohnsonProducers: Kristen Farrah Medical Notes: The Shocking Veteran Suicide Trends, The Best Time To Induce Labor, And The Mental Health Of College StudentsThe tides may finally be turning on veteran suicide. A new treatment for seizures may soon be possible without the need for invasive brain surgery. When it comes to inducing labor, success may be all in the timing. The stigma surrounding mental health on campus is fading. Host: Maayan Voss de Bettancourt Producer: Kristen Farrah Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Why Are Kidney Stones Skyrocketing In Young Girls?Kidney stones, historically associated with middle-aged men, are now being diagnosed at an increasing rate in young girls. Though stones can remain undetected for years, they often cause extreme pain and nausea once they move into the ureter. Our expert discusses treatment options and possible reasons we're seeing more cases in younger patients.  Guest: Dr. Greg Tasain, attending pediatric urologist, Children's Hospital of Philadelphia, professor of surgery, University of Pennsylvania Perelman School of Medicine Host: Greg Johnson  Producers: Kristen Farrah Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In this episode on “Public awareness of urinary tract infections and the fight against antimicrobial resistance”, Assoc. Prof. Z. Tandoğdu (TR) is joined by Prof. G. Bonkat (CH) and Mrs. J.M. Meijlink (NL) to address one of today's most pressing global health challenges. UTIs are among the most common bacterial infections worldwide, yet they are often wrongly perceived as minor conditions. This misconception can lead to overuse or misuse of antibiotics, fuelling the rapid spread of antimicrobial resistance.Prof. Bonkat shares insights from the EAU Guidelines on how responsible prescribing and clinical practice can help prevent unnecessary antibiotic use. Mrs. Meijlink shares the patient perspective, stressing the importance of accurate information and clear communication between doctors and patients.Together, the speakers explore how awareness campaigns, education, and collaboration across healthcare and patient communities are essential to reducing the burden of UTIs. They emphasise that antimicrobial resistance already causes millions of deaths each year and requires urgent, coordinated action.The discussion highlights practical steps for clinicians and patients alike, while reminding listeners that sustainable management of UTIs depends on both medical expertise and active public involvement.AcknowledgmentThis activity is supported by an educational grant from our industry partner - GSK, with no involvement in the programme or speaker selection.For more EAU podcasts, please go to your favourite podcast app and subscribe to our podcast channel for regular updates: Apple Podcasts, Spotify, EAU YouTube channel.

Everyday chemicals from pesticides, plastics, and flame retardants act like hidden antibiotics in your gut, killing beneficial bacteria that support digestion, immunity, and metabolic health Researchers identified 168 common industrial and agricultural chemicals that slowed or stopped the growth of healthy gut microbes, including key species that protect your gut lining and reduce inflammation Some gut bacteria exposed to these chemicals became more resistant to antibiotics, which weakens your future ability to fight infections when antibiotics are truly needed Even low, daily exposures from food, water, air, and household items were enough to disrupt gut bacteria, meaning chronic symptoms like bloating, fatigue, and food sensitivities often trace back to environmental sources, not just diet Reducing chemical exposure while actively supporting gut bacteria helps restore microbial balance, strengthen your gut barrier, and improve energy, immune resilience, and overall health from the inside out

It's getting harder to avoid antibiotics in our food supply.

The benefits of sauna and sunlight during winter monthsApplied Behavioral Analysis in autism treatmentWhat are good supplements to take for HPV virus?

I was diagnosed with follicular lymphoma, but my symptoms may be caused by something else, per my oncologistI've been taking acidophilus and eating yogurt, but still have diarrhea for the last five months since taking a round of antibioticsThe consequences of antibiotic useMy carotid artery intima-media thickness shows higher than normal thickness. Should I be concerned?

Good morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today, we delve into the exciting, yet challenging, landscape of gene therapies and their potential to revolutionize healthcare. Recent scientific advancements have pushed the boundaries of what's possible, offering potential lifetime cures for diseases once considered incurable. However, this breakthrough comes with a significant economic caveat: the staggering cost of these therapies, often ranging between $3 to $4 million per patient. This price tag presents a formidable challenge to current healthcare infrastructures.The disconnect between these innovative treatments and existing payment systems is evident in what industry experts term the "$4 million payment problem." Therapies like Lenmeldy and Hemgenix highlight this issue. Lenmeldy, for instance, can prevent metachromatic leukodystrophy with a single infusion priced at $4.25 million, while Hemgenix offers a cure for hemophilia B at $3.5 million. These therapies effectively convert lifelong treatment costs into a singular, substantial payment, challenging traditional insurance models that are built to spread costs over time.The primary obstacle is not the efficacy of these treatments but rather the financial and logistical infrastructures needed to support them. The current insurance model is ill-equipped to handle such large, one-time payments. Employers who often provide health insurance face a dilemma: investing millions in curing an employee who might leave the company shortly after receiving treatment could result in significant financial risk and disincentivizes employers from covering such therapies.Enter Aradigm Health, which has emerged as a potential solution to this conundrum. Aradigm aims to create an "infrastructure layer" specifically for these high-cost cures. With $20 million in funding backing their initiative, Aradigm seeks to pool financial risk across multiple employers, thus mitigating the impact of substantial individual claims. Their model involves employers contributing a fixed monthly fee into a shared fund that covers these expensive treatments when needed. This approach distributes financial volatility across a broader base rather than placing it on individual employers.Aradigm's strategy is not only about financial solutions but also about streamlining logistical complexities associated with delivering gene therapies. Their patient journey management includes coordinating with biotech companies for manufacturing schedules, arranging travel and accommodation for patients and families, and ensuring seamless insurance paperwork handling. This comprehensive support system reduces barriers that often delay or disrupt treatment delivery.Operating as a public benefit corporation with a "cost-plus" model, Aradigm ensures that any surplus from lower-than-expected claims is returned to employers rather than kept as profit. This aligns incentives towards patient care rather than profit maximization. Their approach highlights a critical need within the biotech and pharmaceutical industries: developing adaptable infrastructures that align with rapid scientific advancements.Meanwhile, Amgen has secured significant ground in 2023 with its second FDA approval for Uplizna in treating generalized myasthenia gravis—a chronic autoimmune neuromuscular disorder characterized by varying degrees of skeletal muscle weakness. Uplizna's mechanism involves targeting CD19 on B cells implicated in autoimmune diseases' pathogenesis. This expansion marks an advancement in therapeutic options for patients and underscores Amgen's growing footprint in treating complex autoimmune conditions.GlaxoSmithKline has also made headlines with Blujepa, marking it as the first new class of antibiotics for gonorrhea in over three decades while receiving approval for treating uncomplicSupport the show

The new National Food Council meets for the first time to start developing Australia's food strategy, an SA company launches a new non-terrestrial 5G network for industries such as farming and mining, and SA researchers win a grant to study how soil microbes could help tackle antibiotic resistance.

Pain relief medications like acetaminophen and ibuprofen are staples in everyday care—but emerging research suggests they may play a role in antibiotic resistance. This episode reviews recent findings, explores how these common drugs may influence bacterial response to antibiotics, and highlights pharmacist‑specific considerations. You will walk away with practical insights to support informed medication use and strengthen antibiotic stewardship.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsGUESTHunter O. Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship Coordinator, SSM HealthAdjunct Clinical Assistant Professor, University of Kansas School of PharmacyRachel Maynard has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated.Pharmacists, REDEEM YOUR CPE HERE!CPE is available to Health Mart franchise members onlyTo learn more about Health Mart, click here: https://join.healthmart.com/CPE INFORMATION Learning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe emerging evidence on how common OTC pain medications may influence antibiotic resistance.2. Identify pharmacist strategies to optimize analgesic and antibiotic use while supporting antimicrobial stewardship.0.05 CEU/0.5 HrUAN: 0107-0000-25-372-H01-PInitial release date: 12/8/2025Expiration date: 12/8/2026Additional CPE details can be found here.

Pain relief medications like acetaminophen and ibuprofen are staples in everyday care—but emerging research suggests they may play a role in antibiotic resistance. This episode reviews recent findings, explores how these common drugs may influence bacterial response to antibiotics, and highlights pharmacist‑specific considerations. You will walk away with practical insights to support informed medication use and strengthen antibiotic stewardship.HOSTRachel Maynard, PharmDGameChangers Podcast Host and Clinical Editor, CEimpactLead Editor, PyrlsHunter O. Rondeau, PharmD, BCIDP, AAHIVPAntimicrobial Stewardship Coordinator, SSM HealthAdjunct Clinical Assistant Professor, University of Kansas School of PharmacyRachel Maynard has no relevant financial relationships with ineligible companies to disclose. Hunter Rondeau is a consultant for Pyrls, a speaker for ASHP, and was a speaker for ACCP (ended October 2025) and Vituity (ended May 2025). All relevant financial relationships have been mitigated. CPE REDEMPTIONThis course is accredited for continuing pharmacy education! Click the link below that applies to you to take the exam and evaluation:If you are already enrolled in this course, click here to redeem your credit. To purchase this episode and claim your CPE credit, click here.CPE INFORMATIONLearning ObjectivesUpon successful completion of this knowledge-based activity, participants should be able to:1. Describe emerging evidence on how common OTC pain medications may influence antibiotic resistance.2. Identify pharmacist strategies to optimize analgesic and antibiotic use while supporting antimicrobial stewardship.0.05 CEU/0.5 HrUAN: 0107-0000-25-372-H01-PInitial release date: 12/8/2025Expiration date: 12/8/2026Additional CPE details can be found here.Follow CEimpact on Social Media:LinkedInInstagram

Send us a textGood morning from Pharma Daily: the podcast that brings you the most important developments in the pharmaceutical and biotech world. Today we dive into some of the most significant and exciting advancements shaping the industry.Let's start with a breakthrough coming out of recent clinical trials. A novel approach to treating Alzheimer's disease is making waves. Researchers have been focusing on a monoclonal antibody designed to target amyloid-beta plaques in the brains of patients suffering from this debilitating condition. The latest Phase 3 trial results have shown a promising reduction in cognitive decline among participants, offering a glimmer of hope for millions affected by Alzheimer's worldwide. The study, conducted over 18 months, involved more than 1,500 patients and demonstrated a statistically significant slowing of disease progression compared to placebo. This could mark a pivotal moment in Alzheimer's treatment, shifting the paradigm from symptomatic relief to disease modification.In regulatory news, the FDA has granted approval to a new gene therapy for hemophilia B. This therapy, developed using cutting-edge CRISPR technology, offers a potential cure for patients who have long relied on regular infusions to manage their bleeding disorder. By directly editing the genes responsible for clotting factor production, this therapy can potentially provide long-term relief with just a single administration. The approval follows extensive clinical trials that showed sustained increases in clotting factor levels and a dramatic reduction in bleeding episodes among participants. This development not only underscores the growing impact of genomic medicine but also highlights the regulatory body's commitment to advancing innovative treatments that meet unmet medical needs.Shifting focus, there's an intriguing trend emerging in oncology drug development. The industry is increasingly adopting personalized medicine approaches, tailoring treatments based on individual genetic profiles. This shift is particularly evident in the rise of targeted therapies and combination regimens designed to tackle cancer at its genetic roots. A recent study demonstrated how combining targeted therapies with immune checkpoint inhibitors can enhance treatment efficacy in certain types of cancer, such as melanoma and non-small cell lung cancer. By understanding the specific mutations driving tumor growth and leveraging the body's immune response, these combinations are setting new standards for cancer care.In another significant development, researchers have unveiled promising results from an innovative mRNA vaccine trial aimed at combating infectious diseases beyond COVID-19. The technology, which gained prominence during the pandemic, is now being applied to other viral threats like influenza and RSV. Early-phase clinical trials have shown robust immune responses and favorable safety profiles, suggesting mRNA vaccines could soon revolutionize how we approach vaccination for a variety of pathogens. This versatility and rapid development timeline make mRNA platforms particularly attractive for addressing emerging infectious diseases swiftly.Meanwhile, a new study has raised awareness about antibiotic resistance—a growing concern globally. Scientists have developed an advanced diagnostic tool capable of rapidly identifying bacterial infections and their resistance profiles within hours instead of days. This innovation can significantly impact how clinicians prescribe antibiotics, ensuring targeted treatments that minimize resistance development. By providing real-time insights into bacterial genetics and resistance mechanisms, this tool empowers healthcare providers to make informed decisions that preserve antibiotic efficacy for future generations.Lastly, let's toSupport the show

The use of antibiotics in treating livestock in the UK has fallen, according to a new report published by the Veterinary Medicines Directorate, which is a government agency. Using high levels of antibiotics in farming can lead to people developing resistance to life-saving antibiotics.The Alliance to Save Our Antibiotics, which was set up to reduce antibiotic use in farm animals, through better livestock husbandry, has just published its own report into antibiotic drug use, particularly in pigs and poultry. It says poultry producers are still using too many ionophores, a kind of medicine to treat parasites, and it wants ionophores to be classified as antibiotics.All week, we're taking a global perspective on farming as delegates at COP 30 in Brazil discuss food production and reducing its impact on the climate. One UK businessman has come up with a system for harvesting the straw left over from rice. It's usually allowed to rot in the fields, or it's burnt but Craig Jamieson has developed a special machine to harvest it and it's now being trialled in the Philippines.We celebrate the farm business that's won the Future Farming award in the BBC's Food and Farming Awards.Presenter: Anna Hill Producer: Rebecca Rooney

Sepsis and bloodstream infections (BSIs) are common and cause millions of deaths each year, with a disproportionate burden in low-income and middle-income countries. Tune in to learn from Jasmine R. Marcelin, MD, FACP, FIDSA, how inadequate antibiotic coverage can be linked to increased mortality and length of stay and how unnecessary broad-spectrum antibiotics can drive antimicrobial resistance. Topics covered include:The worldwide burden of sepsis and BSIsThe ongoing threat of antimicrobial resistanceUS and global health disparities in sepsis, BSI, and antimicrobial resistanceBarriers toward optimizing antibiotic use in BSIsPresenter:Jasmine R. Marcelin, MD, FACP, FIDSAAssociate Professor, Infectious DiseaseAssociate Medical Director, Antimicrobial Stewardship ProgramVice Chair for Belonging and Community Engagement, Department of Internal MedicineCo-Director, Digital Innovation & Social Media Strategy, Division of Infectious DiseasesUniversity of Nebraska Medical CenterOmaha, NebraskaLink to full program and downloadable slides:https://bit.ly/4inoXCxGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.  Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Unnecessary broad-spectrum antibiotics can drive antimicrobial resistance and cause adverse events, whereas inadequate antibiotic coverage is linked to increased mortality and length of stay for patients with bloodstream infections (BSIs). Listen now to learn from Jose Alexander, MD, D(ABMM), CIC, FCCM, SM/MB(ASCP), how to use rapid genotypic and phenotypic antimicrobial susceptibility testing results to inform antibiotic selection for patients with gram-negative BSIs. Topics covered include:Typical patterns of intrinsic antibiotic susceptibility and resistance in EnterobacteralesMechanisms of resistance in gram-negative bacteriaGenotypic rapid diagnostic tests for BSIsResistance markers for earlier targeted therapyRapid phenotypic antimicrobial susceptibility test platforms for blood culturesPresenter:Jose Alexander, MD, D(ABMM), CIC, FCCM, SM/MB(ASCP)Medical and Public Health MicrobiologistMedical and Technical Director of MicrobiologyAdventHealthOrlando, FloridaLink to full program and downloadable slides:https://bit.ly/4inoXCxGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Rapid phenotypic antimicrobial susceptibility testing (AST) significantly reduces time to actionable results and can improve antibiotic decision-making for patients with bloodstream infections. Listen in to learn from Michael P. Veve, PharmD, MPH, how to optimally integrate rapid phenotypic AST into clinical practice, including incorporation into your existing antimicrobial stewardship workflow. Topics covered include:Considerations for implementationDecision-making steps for implementationThe role of antimicrobial stewardship programs in AST workflowPresenter:Michael P. Veve, PharmD, MPHClinical Associate ProfessorDepartment of Pharmacy PracticeEugene Applebaum College of Pharmacy and Health SciencesWayne State UniversityClinical Pharmacy Specialist, Infectious DiseaseHenry Ford HospitalDetroit, MichiganLink to full program and downloadable slides:https://bit.ly/4inoXCxGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Antibiotic resistance is a rapidly growing global threat, driven by misused medications and the natural evolution of bacteria. Modern technologies such as AI-guided phage therapy and AMR surveillance are opening new pathways to detect, target, and treat resistant infections more precisely. Tackling this crisis, however, requires a unified “One World” approach where countries share data, resources, and innovations to protect human, animal, and environmental health. I'm thrilled to be joined by two of our biology students, Maisie and Tilly who will have conducted and will share their own research into this fascinating subject.

Dr Megan Dempster, a researcher at Wits’ Vaccines & Infectious Disease Analytics unit, speaks to John Maytham about a study that found that two types of bacteria are responsible for or more than half the infections that kill newborns and infants in Soweto. Presenter John Maytham is an actor and author-turned-talk radio veteran and seasoned journalist. His show serves a round-up of local and international news coupled with the latest in business, sport, traffic and weather. The host’s eclectic interests mean the program often surprises the audience with intriguing book reviews and inspiring interviews profiling artists. A daily highlight is Rapid Fire, just after 5:30pm. CapeTalk fans call in, to stump the presenter with their general knowledge questions. Another firm favourite is the humorous Thursday crossing with award-winning journalist Rebecca Davis, called “Plan B”. Thank you for listening to a podcast from Afternoon Drive with John Maytham Listen live on Primedia+ weekdays from 15:00 and 18:00 (SA Time) to Afternoon Drive with John Maytham broadcast on CapeTalk https://buff.ly/NnFM3Nk For more from the show go to https://buff.ly/BSFy4Cn or find all the catch-up podcasts here https://buff.ly/n8nWt4x Subscribe to the CapeTalk Daily and Weekly Newsletters https://buff.ly/sbvVZD5 Follow us on social media: CapeTalk on Facebook: https://www.facebook.com/CapeTalk CapeTalk on TikTok: https://www.tiktok.com/@capetalk CapeTalk on Instagram: https://www.instagram.com/ CapeTalk on X: https://x.com/CapeTalk CapeTalk on YouTube: https://www.youtube.com/@CapeTalk567 See omnystudio.com/listener for privacy information.

Matters Microbial #112: Bacterial Size, Stress, and Antibiotic Resistance October 17, 2025 Today Dr. Petra Levin, the George and Irene Freiberg Professor of Biology at Washington University in St. Louis joins the #QualityQuorum to discuss her work with bacterial cell size, environmental stress on bacteria, and antibiotic resistance. Host: Mark O. Martin Guest: Petra Levin Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode An overview of the periplasm, found in Gram negative bacteria. An overview of beta-lactam antibiotics. The field of quantitative microbiology. An overview of B. subtilis.  An overview of E. coli.  An overview of Klebsiella.  The biography of Barbara McClintock, “A Feeling for the Organism.” A video explanation of the lac operon of E. coli. The LTEE program (Long Term Evolution Experiment) founded by Dr. Rich Lenski. The nomenclature of monoderm and diderm bacteria. A video explanation of peptidoglycan in bacteria. Penicillin binding proteins (PBP) and antibiotic resistance. A video about cell division in E. coli. A famous article coauthored by Dr. Elio Schaechter that describes cell growth and cell size in bacteria. A related article by Dr. Levin and colleagues. An overview of ESKAPE bacteria. An article from Dr. Levin's research group describing the relationship between pH and antibiotic resistance. An article about persister cells and their relevance to antibiotic resistance. Dr. Levin's faculty website. Dr. Levin's very interesting laboratory website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Send us a textDrug-resistant germs are hidden killers in more than one way. Not only are the microbes invisible to the human eye, in many places, they're invisible because people simply are not looking for them systematically.Doctors often do not know what infections their patients have and treat them based on best guesses, which allows for ineffective treatments and exacerbates drug resistance. Policymakers don't know which infections are most common among populations and cannot make informed decisions about needed treatments or vaccines.This is a major problem across Africa and a new report shows just how complex the problem is.The Mapping AMR and Antimicrobial use Partnership (MAAP), which included the One Health Trust as well as the African Society for Laboratory Medicine; Africa CDC; the East, Central, and Southern Africa Health Community; Innovative Support to Emergencies, Diseases, and Disasters, a nonprofit focused on technology and communication;  the clinical research group IQVIA; and the West African Health Organization, collected data from laboratories from 14 countries in Africa (Burkina Faso, Cameroon, Gabon, Ghana, Kenya, Eswatini, Malawi, Nigeria, Senegal, Sierra Leone, Tanzania, Uganda, Zambia, and Zimbabwe). “The study revealed significant gaps in bacteriology testing capacities,” the group, whose work was paid for by the UK government's Fleming Fund, wrote in PLoS Medicine.It's the biggest survey yet of testing for antimicrobial resistance – AMR or drug resistance – in Africa.Among the gaps: too little testing overall, a lack of laboratory capacities, and poor coordination and analysis of records. Many records were kept only on paper, which made them almost impossible to access.None of this surprises Dr. Sabiha Essack, South African Research Chair in Antibiotic Resistance and One Health and Professor in Pharmaceutical Sciences at the University of KwaZulu-Natal. In an ideal world, she says, a doctor, nurse or other professional should see a patient, test them to see what specific microbe is causing an infection, check to see which drugs will successfully fight that germ, and then treat the patient accordingly.Cheap point-of-care tests should be available everywhere and the results of those tests should be entered into systems that officials can use to make policy decisions, she says. Listen as she tells One World, One Health host Maggie Fox other ways to improve our knowledge about the drug-resistant infections that lurk out there. Want to know more? You can find One World, One Health episodes on drug-resistant infections in cancer patients; superbugs and microplastics; the personal toll of antibiotic resistance; one woman's antibiotic resistance nightmare; how to prevent drug resistance, and more.

Listen in as Dr Trevor Van Schooneveld explores rapid syndromic testing for gastrointestinal and joint infections and discusses how to apply best practices for diagnostic and antimicrobial stewardship in syndromic testing. Topics covered include: Who should be tested for infectious diarrheaTypes of gastrointestinal syndromic panelsTypes of syndromic panels for joint infectionsReal-world applications for joint syndromic panelsPresenters: Trevor Van Schooneveld, MDProfessor, Division of Infectious DiseasesMedical Director, Antimicrobial Stewardship ProgramDepartment of Internal MedicineUniversity of Nebraska Medical CenterOmaha, NebraskaLink to full program: https://bit.ly/4mHOTtWGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify. 

Matters Microbial #104: Antibiotic “Tolerance” and Biofilms August 21, 2025 Today, Dr. Boo Shan Tseng, Associate Professor at the University of Nevada Las Vegas School of Life Sciences, joins the #QualityQuorum to discuss bacterial biofilms and antibiotic tolerance.  Host: Mark O. Martin Guest: Boo Shan Tseng Subscribe: Apple Podcasts, Spotify Become a patron of Matters Microbial! Links for this episode A video overview of biofilms. A comprehensive review article on biofilms. An article describing the impact biofilms have on disease. An article describing the impact of biofilms on implanted medical devices. A link to the Center for Biofilm Engineering at Montana State University that has MANY links of interest. An overview of biofilm development. An overview of confocal laser microscopy. Studying biofilms in flow cells. An article about the role proteins play in biofilm formation, which intersects with the Tseng group's research. The technique of single cell RNA seq. The technique of mRNA-FISH. An article about porins in bacteria, and how that can relate to antibiotic resistance. An article by Dr. Tseng and coworkers on the eDNA and biofilms discussed today. A lovely video of Dr. Tseng talking about the research she and her colleagues carry out in the laboratory. Dr. Tseng's biography from the American Society for Microbiology. Dr. Tseng's laboratory group website with wonderful links and images. Dr. Tseng's faculty website. Intro music is by Reber Clark Send your questions and comments to mattersmicrobial@gmail.com

Mycoplasma genitalium or Mgen is an STI most people don't know exists - and yet it's super common and can be very difficult to treat due to antibiotic resistance. We chat to Professor Catriona Bradshaw covering everything from stats and symptoms, to getting tested and treatments.DM us your thoughts, questions, topics, or to just vent at @triplejthehookup on IG or email us: thehookup@abc.net.auThe Hook Up is an ABC podcast, produced by triple j. It is recorded on the lands of the Wurundjeri people of the Kulin nation. We pay our respects to elders past and present. We acknowledge Aboriginal and Torres Strait Islander peoples as the First Australians and Traditional Custodians of the land where we live, work, and learn.

HIV, superbugs, and standards—oh my! In this episode of Absolute Gene-ius, we explore the frontier of infectious disease research with Dr. Jesús Mingorance, researcher at Hospital Universitario La Paz in Madrid. His research is translational and uses digital PCR, qPCR, sequencing, and more.Dr. Mingorance walks us through his application of ultra-sensitive PCR methods to track HIV-2 viral loads—particularly in challenging cases where standard assays fall short. He shares how digital PCR enabled detection in samples where conventional tests failed, and how it's becoming essential for assay calibration and microbial quantification. He also dives into the endemic challenges of carbapenem-resistant Klebsiella pneumoniae in hospitals, revealing the clinical and epidemiological importance of quantifying pathogen load within the microbiome.In the career corner, Dr. Mingorance recounts his unconventional journey—from humanities student to biologist inspired by a single sentence about DNA. With humor and honesty, he reflects on the patience needed in science, the value of good questions, and the importance of mentoring new scientists. “Biology is beautiful,” he reminds us. We agree.Visit the Absolute Gene-ius pageto learn more about the guests, the hosts, and the Applied Biosystems QuantStudio Absolute Q Digital PCR System. 

Listen in as Michael Satlin, MD, MS, FIDSA,explores rapid syndromic testing for bloodstream infections and discusses how to apply best practices for diagnostic and antimicrobial stewardship in syndromic testing.Topics covered include:Types of upper and lower respiratory infection panelsConsiderations for when to use respiratory syndromic testingHow to use syndromic testing to guide both therapy escalation and de-escalationHow syndromic testing fits in with traditional testing methods, such as culture, antimicrobial susceptibility testing, Gram stain, and BAL cell count Presenter:Michael Satlin, MD, MS, FIDSAAssociate Professor of Medicine and Pathology and Laboratory MedicineWeill Cornell MedicineNew York, New YorkLink to full program: https://bit.ly/3UAB1oUGet access to all of our new podcasts by subscribing to the CCO Infectious Disease Podcast on Apple Podcasts, Google Podcasts, or Spotify.

One of the greatest medical breakthroughs of the twentieth century is set to become one of the biggest threats of the twenty-first - but what can be done to stem the rising tide of antibiotic resistance? In this episode, host Caroline Dodds Pennock speaks with Liam Shaw, biologist and author of Dangerous Miracle: A Natural History of Antibiotics – and How We Burned Through Them. From the miraculous discovery of penicillin to the industrial-scale production that changed healthcare and agriculture forever, Shaw takes us through the fascinating - and cautionary - story of these ‘fossil fuels of medicine.' Together, they explore when and how the threat of resistance emerged, the roles of Big Pharma and industrial farming in accelerating the crisis, and the parallels with climate change in how we've squandered a finite resource. But as MIT researchers recently announced a breakthrough with AI designing antibiotics for gonorrhoea and MRSA superbugs, Shaw also outlines clear roadmaps for the future - including bold proposals for transforming the way we develop, patent and pay for antibiotics. If you'd like to become a Member and get access to all our full conversations, plus all of our Members-only content, just visit intelligencesquared.com/membership to find out more. For £4.99 per month you'll also receive: - Full-length and ad-free Intelligence Squared episodes, wherever you get your podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series - 15% discount on livestreams and in-person tickets for all Intelligence Squared events  ...  Or Subscribe on Apple for £4.99: - Full-length and ad-free Intelligence Squared podcasts - Bonus Intelligence Squared podcasts, curated feeds and members exclusive series … Already a subscriber? Thank you for supporting our mission to foster honest debate and compelling conversations! Visit intelligencesquared.com to explore all your benefits including ad-free podcasts, exclusive bonus content and early access. … Subscribe to our newsletter here to hear about our latest events, discounts and much more. https://www.intelligencesquared.com/newsletter-signup/ Learn more about your ad choices. Visit podcastchoices.com/adchoices Learn more about your ad choices. Visit podcastchoices.com/adchoices

What percentage of meat samples test positive for drug residue violations?